Longevity

In 2025, the first human data for in vivo PCSK9 base editing showed large, durable LDL-C drops after a single infusion. If safety holds and access follows, one-and-done edits could shift heart disease prevention from chronic care to permanent risk cut.

Retro Biosciences is set to begin first human testing in Australia of RTR242, an autophagy-activating pill aimed at Alzheimer’s. Paired with OpenAI’s GPT‑4b micro reprogramming work, it is a pivotal test for geroscience in the clinic.

Retro Biosciences will dose its first Alzheimer’s patients in Australia with RTR242, an autophagy-boosting pill. The study is a test case for proving longevity mechanisms through disease endpoints, and for a new path in regulation and funding.

In 2025 the FDA gave Loyal’s canine longevity pill a reasonable expectation of effectiveness, opening the first practical regulatory path for lifespan extension. Here is how the dog route could speed safe human geroprotectors.

Swiss Re projects that broad GLP‑1 adoption could trim U.S. deaths by 6.4% and the U.K. by 5.1% by 2045. We stress‑test that forecast, parse the latest outcomes data, and map the ripple effects for insurers, pensions, and public health.

On September 14, 2025, Retro Biosciences said its inaugural trial, RTR242, will begin dosing in Australia by year end. Framed as an Alzheimer’s study, the autophagy pill doubles as a longevity play with a regulatory twist.

A quiet shift is underway in biology. With AI-designed proteins, complete synthetic genomes, and living microrobots, we are moving from editing life to writing it. Here is what it means, why it matters, and how to steer it.

Fresh ESC 2025 readouts on in vivo PCSK9 and Lp(a) gene editing point to durable LDL and Lp(a) cuts after a single infusion. If confirmed, this is the first pay-once, long-horizon risk modifier for healthspan, not just heart disease.